SCHEMBL4820364

SCHEMBL4820364

Cc1ccc2c3c(ccc2n1)OCC(CN1CC(C(C)c2c[nH]c4ccc(F)cc24)C1)O3

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 20/20 0.56
SLC6A4 P31645 1/20 0.52
DRD2 P14416 3/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C8 P10632 1/20 0.45
DRD4 P21917 1/20 0.45
CYP2C19 P33261 1/20 0.45
DRD3 P35462 1/20 0.45
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4828108 0.85 HTR1A (0.58) HTR1ASLC6A4DRD2CYP3A4CYP2C8
SCHEMBL6629005 0.81 HTR1A (0.60) HTR1ASLC6A4DRD2CYP3A4CYP2C8
SCHEMBL4820337 0.80 HTR1A (0.57) HTR1ASLC6A4DRD2CYP3A4CYP2C8
SCHEMBL6630467 0.79 HTR1A (0.81) HTR1ASLC6A4DRD2CYP3A4CYP2C8
SCHEMBL4827109 0.77 HTR1A (0.58) HTR1ASLC6A4DRD2CYP3A4CYP2C8
SCHEMBL4820939 0.76 HTR1A (0.57) HTR1ASLC6A4DRD2CYP3A4CYP2C8
SCHEMBL4820305 0.75 HTR1A (0.66) HTR1ASLC6A4DRD2CYP3A4CYP2C8
SCHEMBL6629168 0.75 HTR1A (0.82) HTR1ASLC6A4DRD2CYP3A4CYP2C8
SCHEMBL5233867 0.75 HTR1A (0.52) HTR1ASLC6A4
SCHEMBL4826927 0.74 HTR1A (0.62) HTR1ASLC6A4DRD2CYP3A4CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419986-B2 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans WYETH (US) 2008-09-02 US claimed
US-20060293301-A1 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans WYETH (US) 2006-12-28 US claimed
US-7135479-B2 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans WYETH (US) 2006-11-14 US claimed
US-20040132714-A1 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans WYETH 2004-07-08 US claimed
US-7419986-B2 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans WYETH (US) 2008-09-02 US disclosed
US-7335666-B2 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans WYETH (US) 2008-02-26 US disclosed
US-20070004702-A1 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans WYETH (US) 2007-01-04 US disclosed
US-20060293301-A1 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans WYETH (US) 2006-12-28 US disclosed
US-20040132714-A1 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans WYETH 2004-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293301-A1 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans CRH, HTR5A, DBH HTR1A 121/4885SLC6A4 216/4885DRD2 20/4885
US-20070004702-A1 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans CRH, CYP19A1, HTR5A HTR1A 88/4885SLC6A4 263/4885DRD2 22/4885
US-20040132714-A1 Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans CYP19A1, CRH, CYP17A1 HTR1A 64/4885SLC6A4 278/4885DRD2 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.